Summary & Overview
CPT 64653: Chemical Injection to Eccrine Glands for Non‑Axillary Hyperhidrosis
CPT code 64653 identifies a procedure in which a chemical compound is injected into eccrine sweat glands outside the axillae to treat hyperhidrosis. This targeted, outpatient procedure addresses focal excessive sweating in regions such as palms, soles, or craniofacial areas and is relevant to dermatology, plastic surgery, and outpatient procedural practices. Nationally, the code matters because it captures a non-surgical, focal treatment option for a common and quality-of-life–affecting condition and is used to track utilization, coverage decisions, and payment policy for non-axillary hyperhidrosis therapies.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the procedure, payer coverage themes, common billing modifiers, and benchmarks where available. The publication also outlines coding considerations, typical sites of service, and policy or coverage trends that may influence access to this non-axillary hyperhidrosis treatment. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 64653 describes injection of a chemical compound into eccrine glands in areas other than the axillae to treat hyperhidrosis (excessive sweating). The procedure targets sweat-producing glands with localized chemical treatment to reduce sweating in affected non-axillary regions.
Service type: Procedure — chemical injection for hyperhidrosis treatment
Typical site of service: Outpatient clinic or ambulatory procedure setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a dermatology or outpatient procedural clinic with focal, bothersome primary hyperhidrosis of non-axillary sites (for example palms, soles, or craniofacial areas) that has failed conservative management such as topical antiperspirants, iontophoresis, or oral anticholinergics. The patient reports socially or occupationally limiting excessive sweating despite prior therapies. The provider (commonly a dermatologist, neurologist, or plastic surgeon) documents patient history, performs a focused physical exam including site mapping of hyperhidrotic areas, and discusses risks and expected transient effects of a chemical sympathectomy or eccrine gland-directed chemodenervation. In the procedure suite or minor procedure room, the provider prepares the treatment area, identifies treatment sites, and administers the chemical compound intradermally or intraglandularly to the eccrine glands in the non-axillary region. Post-procedure monitoring includes short observation for acute adverse effects, written aftercare instructions, and scheduling follow-up to assess efficacy and possible repeat treatments. Billing uses 64653 for chemical denervation of eccrine glands in areas other than the axillae; documentation links to the specific non-axillary site, previous treatments tried, informed consent, the agent used, quantity/volume, and immediate post-procedure status.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Normal/professional service |